Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-04-05
2011-04-05
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C530S328000
Reexamination Certificate
active
07919099
ABSTRACT:
The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines.
REFERENCES:
patent: 5712380 (1998-01-01), Kendall et al.
patent: 6383486 (2002-05-01), Davis-Smyth et al.
patent: 7514084 (2009-04-01), Tahara et al.
patent: 7556809 (2009-07-01), Romero et al.
patent: 2005/1175624 (2005-08-01), Romero et al.
patent: 2006/0216301 (2006-09-01), Tahara et al.
patent: 1 548 032 (2005-06-01), None
patent: WO 02/072627 (2002-09-01), None
patent: WO 03/042243 (2003-05-01), None
patent: WO 03/086450 (2003-10-01), None
patent: WO 2004/024766 (2004-03-01), None
Kubo et al, J Immunology 152: 3913-3921, 1994.
Baxevanis, C. N, et al., “Immunogenic HER-2
eu peptides as tumor vaccines,”Cancer Immunol Immunother, 2006, vol. 55, No. 1, pp. 85-95. Epub Oct. 27, 2005.
Ferrara, N. et al., “The Biology of Vascular Endothelial Growth Factor,”Endocrine Reviews, 1997, vol. 18, No. 1, pp. 4-25.
Leggatt, G. R, et al., “The Importance of Pairwise Interactions Between Peptide Residues in the Delineation of TCR Specificity,”J Immunol, 1998, vol. 161, No. 9, pp. 4728-4735.
Mestas, J, et al., “Of Mice and Not Men: Differences between Mouse and Human Immunology,”J Immunol, 2004, vol. 172, No. 5, pp. 2731-2738.
Plate, K. H, et al., “Vascular Endothelial Growth Factor and Glioma Angiogenesis: Coordinate Induction of Vegf Receptors, Distribution of Vegf Protein and Possible In Vivo Regulatory Mechanisms,”Int J Cancer, 1994, vol. 59, No. 4, pp. 520-529.
Shibuya, M. et al., “Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to thefmsfamily,”Oncogene, 1990, vol. 5, No. 4, pp. 519-524.
Kondo et al.; “Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class 1 molecules”; 1995;J. Immunol.; vol. 155, No. 9, pp. 4307-4312.
Kubo et al.; “Definition of specific peptide motifs for four major HLA-A alleles”; 1994;J. Immunol.; vol. 152, No. 8, pp. 3913-3924.
Zaremba et al.; “Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen”; 1997;Cancer Res.; vol. 57, pp. 4750-4757.
Nakatsuru Shuichi
Shibuya Masabumi
Tahara Hideaki
Tsunoda Takuya
Huynh Phuong
Kilpatrick Townsend & Stockton LLP
Oncotherapy Science, Inc.
LandOfFree
Epitope peptides derived from vascular endothelial growth... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Epitope peptides derived from vascular endothelial growth..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epitope peptides derived from vascular endothelial growth... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2687629